ASX Announcement: Penthrox approved in another 22 European countries
12 December 2017
Penthrox approved in another 22 European countries
Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for use in an additional 22 European countries today, further underwriting the confidence that global health authorities have in our dossier.
The Medicine and Healthcare products Regulatory Agency (“MHRA”) issued the Final Assessment Report with the support of all European country authorities noting the Decentralised Procedure (DCP) has been successfully completed. All countries have had the opportunity to review the dossier and in principal agree on the benefits of Penthrox as a widely used analgesic throughout Europe.
For the full ASX Announcement, please refer to the following link: ASX Announcement – ASX Announcement_Penthrox approved in another 22 European countries_121217